Single-dose pharmacokinetics of fosfomycin during continuous venovenous haemofiltration.
暂无分享,去创建一个
M. Zeitlinger | F. Thalhammer | C. Joukhadar | B. Meyer | G. Heinz | P. Dittrich | R. Gattringer | C. Guttmann
[1] C. Quentin,et al. In vitro activity of fosfomycin combined with ceftazidime, imipenem, amikacin, and ciprofloxacin againstPseudomonas aeruginosa , 1997, European Journal of Clinical Microbiology and Infectious Diseases.
[2] T. Staudinger,et al. Pharmacokinetics of teicoplanin during continuous hemofiltration with a new and a 24-h used highly permeable membrane: rationale for therapeutic drug monitoring-guided dosage. , 2004, International journal of clinical pharmacology and therapeutics.
[3] W. Jaeger,et al. How to Calculate Clearance of Highly Protein-Bound Drugs during Continuous Venovenous Hemofiltration Demonstrated with Flucloxacillin , 2003, Kidney and Blood Pressure Research.
[4] M. Zeitlinger,et al. Target site bacterial killing of cefpirome and fosfomycin in critically ill patients. , 2003, International journal of antimicrobial agents.
[5] A. Geppert,et al. Target site penetration of fosfomycin in critically ill patients. , 2003, The Journal of antimicrobial chemotherapy.
[6] K. Ratheiser,et al. Clearance of ceftazidime during continuous venovenous haemofiltration in critically ill patients. , 2002, The Journal of antimicrobial chemotherapy.
[7] F. Allerberger,et al. In vitro activity of fosfomycin in combination with various antistaphylococcal substances. , 2001, The Journal of antimicrobial chemotherapy.
[8] U. Kroh. Pharmacokinetic studies in patients on continuous renal replacement therapies , 2001, Intensive Care Medicine.
[9] F. Crokaert. Pharmacodynamics, a tool for a better use of antibiotics? , 2001, Intensive Care Medicine.
[10] A. Georgopoulos,et al. Distribution and Antimicrobial Activity of Fosfomycin in the Interstitial Fluid of Human Soft Tissues , 2000, Antimicrobial Agents and Chemotherapy.
[11] J. Donauer,et al. Pharmacokinetic principles during continuous renal replacement therapy: drugs and dosage. , 1999, Kidney international. Supplement.
[12] K. Ratheiser,et al. Single-Dose Pharmacokinetics of Meropenem during Continuous Venovenous Hemofiltration , 1998, Antimicrobial Agents and Chemotherapy.
[13] M. A. Marx,et al. Drug dosing adjustments during continuous renal replacement therapies. , 1998, Kidney international. Supplement.
[14] G. Mayer,et al. Multiple‐dose pharmacokinetics of cefpirome in long‐term hemodialysis with high‐flux membranes , 1996, Clinical pharmacology and therapeutics.
[15] M. J. Renedo,et al. Determination of fosfomycin in human urine by capillary gas chromatography: Application to clinical pharmacokinetic studies , 1996 .
[16] S. Cotterill. Antimicrobial prescribing in patients on haemofiltration. , 1995, The Journal of antimicrobial chemotherapy.
[17] Jerome J. Schentag,et al. The Importance of Pharmacokinetic/Pharmacodynamic Surrogate Markers to Outcome , 1995, Clinical pharmacokinetics.
[18] B. Canaud,et al. Pump assisted continuous venovenous hemofiltration for treating acute uremia. , 1988, Kidney international. Supplement.
[19] G. Vinçon,et al. Pharmacokinetics of fosfomycin in hemodialyzed patients. , 1985, Clinical Nephrology.
[20] F. Dalet,et al. Pharmacokinetics of fosfomycin during hemodialysis. , 1977, Chemotherapy.